Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?
about
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert MTB/RIF test for detection of pulmonary tuberculosis and rifampicin resistanceDiagnosis & treatment of tuberculosis in HIV co-infected patients.Point-of-care assays for tuberculosis: role of nanotechnology/microfluidics.Opportunities for Improved Serodiagnosis of Human Tuberculosis, Bovine Tuberculosis, and ParatuberculosisEvaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic reviewCost-effectiveness comparison of Genechip and conventional drug susceptibility test for detecting multidrug-resistant tuberculosis in ChinaThe diagnostic performance of a single GeneXpert MTB/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in MalaysiaRoutine use of microbial whole genome sequencing in diagnostic and public health microbiologyAdvances and challenges in biosensor-based diagnosis of infectious diseases.Simplified microarray system for simultaneously detecting rifampin, isoniazid, ethambutol, and streptomycin resistance markers in Mycobacterium tuberculosisEvaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study.Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest EthiopiaUse of amplified Mycobacterium tuberculosis direct test in respiratory samples from HIV-infected patients in Brazil.Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.Evaluation of Cepheid's Xpert MTB/Rif test on pleural fluid in the diagnosis of pleural tuberculosis in a high prevalence HIV/TB settingA diagnostic accuracy study of Xpert®MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru.Longer hospital stay is associated with higher rates of tuberculosis-related morbidity and mortality within 12 months after discharge in a referral hospital in Sub-Saharan AfricaState of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB controlInfectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic TechnologiesGeneXpert--a game-changer for tuberculosis control?Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy resultsPolymorphisms in isoniazid and prothionamide resistance genes of the Mycobacterium tuberculosis complex.Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa.Reporter phage and breath tests: emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy.Implementation Research to Inform the Use of Xpert MTB/RIF in Primary Health Care Facilities in High TB and HIV Settings in Resource Constrained SettingsThe utility of Xpert MTB/RIF performed on bronchial washings obtained in patients with suspected pulmonary tuberculosis in a high prevalence setting.Performance evaluation of three commercial molecular assays for the detection of Mycobacterium tuberculosis from clinical specimens in a high TB-HIV-burden settingEstimation of D-Arabinose by Gas Chromatography/Mass Spectrometry as Surrogate for Mycobacterial Lipoarabinomannan in Human UrineCost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active TuberculosisRapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS.Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program.Causes of mortality among tuberculosis and HIV co-infected patients in Chiang Rai, Northern Thailand.Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.Tuberculosis drug resistance and outcomes among tuberculosis inpatients in Lilongwe, MalawiApplying new technologies for diagnosing sexually transmitted infections in resource-poor settings.Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda.Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis.
P2860
Q24200879-6DF9E80B-CDFD-4B32-96E8-F413CBB95695Q24201466-F2DF5E12-C741-495F-8F46-F965F54355F6Q24203927-3ABD0011-EC22-47A0-A4CA-097210F2583AQ26991633-3252FFE1-5F93-4253-84F7-011ADAB61D02Q27004505-0C0F21F7-CB04-469F-ABBF-D61918AC66C6Q27495985-D923A89B-9D41-4546-9B99-3679C65188E1Q28481845-E55FF794-22BC-4B99-8B25-6BD85823ED1DQ28534773-614EC263-3E18-4A74-BB65-4E54B1C50185Q28536945-22367CF2-D966-443E-B1AE-747BE45873FCQ28728617-06AC3AA7-1CEA-40F1-A439-833F4E09A5CCQ30434510-D5FAC769-2DAE-44D0-94E8-3B71E232F9CCQ33703304-2D05D80A-3549-4D48-904A-057D836CBDFAQ33742861-A4F5854B-51C3-4078-865F-989B3EECB77BQ33812641-AED53178-5561-48D4-90B8-EDF04DE1CB94Q33852416-5829F16E-E268-4D5C-ADD2-3573BFB003C4Q33924587-5B2A7976-3C6D-416D-B3C3-669CAB96E722Q33933436-D1D47175-45E1-4989-BB27-04C0EF38C626Q34412632-9D7959AB-56A0-4C22-A806-839440568F6BQ34467936-2E6782C2-056E-4A13-8005-1B93EF65148FQ34570912-120E72DD-BEA7-4EB1-BA9C-788EDEF7DA3DQ34608590-24BE3763-8430-4305-B336-E92C820DCC4EQ35129500-A9C7CB51-F0EE-4CB9-8746-0CED8EAB1A57Q35139738-F861F16C-58E5-4A15-A2DD-517E90DBE9BCQ35191465-E313AEEA-A74A-48BB-978A-FD1635C27EBDQ35598939-56CAE5C6-7FE2-4321-AF8D-0483CDB9FDE1Q35639154-AC39876B-A41B-4C52-B2D7-00336C1E01C4Q35647887-F6DE37A5-9239-4841-9D18-97CB06EBD23AQ35777843-2325A65A-60C6-4D22-9D7E-5F88AA775BFDQ35836639-222354EF-565B-49C8-BBD7-AFAE6C4677EBQ35860237-5AC09B1A-5627-466E-9F3B-4C25D39C95E3Q36056621-EC78A7E8-278C-49FC-97D3-2BC8A4B986BBQ36149564-8C2FAE4E-EB0B-43A0-8954-A346EF8ABC9EQ36263610-7888C181-DF9D-4341-8841-F14EE24049A0Q36275494-78A97383-A65C-4C25-AF30-83CF3C7FBFB7Q36311260-672BDB33-72E7-4666-83DB-075E37AD1C76Q36424212-62C125CF-AE2F-4505-A880-B6F2F4D6A0CEQ36656601-607345B4-1576-46D7-890F-8E744DA8590DQ36730383-E4234E25-EAFE-48CD-B7A6-76DAFF91258FQ36843955-F9EA3C50-47AA-49D2-BC03-67451139F826Q37026454-CF7FF480-780F-46BC-B2AB-7A7284F03C5B
P2860
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Xpert(®) MTB/RIF for point-of- ...... mited countries: hype or hope?
@en
Xpert(®) MTB/RIF for point-of- ...... mited countries: hype or hope?
@nl
type
label
Xpert(®) MTB/RIF for point-of- ...... mited countries: hype or hope?
@en
Xpert(®) MTB/RIF for point-of- ...... mited countries: hype or hope?
@nl
prefLabel
Xpert(®) MTB/RIF for point-of- ...... mited countries: hype or hope?
@en
Xpert(®) MTB/RIF for point-of- ...... mited countries: hype or hope?
@nl
P2093
P2860
P356
P1476
Xpert(®) MTB/RIF for point-of- ...... mited countries: hype or hope?
@en
P2093
Lesley Scott
Liesl Page-Shipp
Wendy Stevens
P2860
P304
P356
10.1586/ERM.10.67
P577
2010-10-01T00:00:00Z